Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Neurooncol. 2016 Jan 8;127(2):391–400. doi: 10.1007/s11060-015-2051-3

Fig. 2.

Fig. 2

Examples of data in two patients with opposite trends in number of AnnV + MV; blood samples were taken before, twice during and at the end of CRT. The y-axis is the raw number of MV as recorded by FCM. This value can be multiplied by the dilution factor, 50 and then by ≈2 to account for plasma versus whole blood, in order to estimate the number of MV/mL in blood. Graphs include the timing of critical clinical events (*). Note that numerical value of the axes are not the same in both patients. Patient 1, Fig. 2a has a decreasing slope during CRT and had a recurrence at 580 days and was alive at 818 days. Patient 7, Fig. 2b has an increasing slope with first recurrence at 199 days and an overall survival of 274 days